Skip to main content
Erschienen in: Current Breast Cancer Reports 3/2012

01.09.2012 | Risk, Prevention, and Screening (MC Liu, Section Editor)

Role of Mammography versus Magnetic Resonance Imaging for Breast Cancer Screening

verfasst von: Linei Urban, Cícero Urban

Erschienen in: Current Breast Cancer Reports | Ausgabe 3/2012

Einloggen, um Zugang zu erhalten

Abstract

Mammographic screening has been proven to detect breast cancer at an early stage and to reduce mortality from breast cancer. Nevertheless, some limitations concerning sensitivity, as well as adverse effects such as false negatives and radiosensitivity, has led to a need to search for other screening techniques. Magnetic resonance imaging has been an excellent choice for some specific subgroups, including patients at high risk. However, high cost, low availability, and lack of long-term trials aiming to prove the reduction of mortality have limited magnetic resonance application. Moreover, some points about breast cancer screening still need to be clarified, including overdiagnosis rate, which includes cancers that would not have become clinically significant during the woman’s lifetime, and cost effectiveness. In this review, the authors analyze the role of mammography and magnetic resonance imaging in breast cancer screening for the general and high-risk populations.
Literatur
1.
Zurück zum Zitat Jackman VP. Screening mammography: controversies and headlines. Radiology. 2002;225:323–6.CrossRef Jackman VP. Screening mammography: controversies and headlines. Radiology. 2002;225:323–6.CrossRef
2.
Zurück zum Zitat Tabar L, Yen MF, Vitak B, et al. Mammography service screening and mortality in breast cancer patients: 20-year follow-up before and after introduction of screening. Lancet. 2003;361:1405–10.PubMedCrossRef Tabar L, Yen MF, Vitak B, et al. Mammography service screening and mortality in breast cancer patients: 20-year follow-up before and after introduction of screening. Lancet. 2003;361:1405–10.PubMedCrossRef
3.
Zurück zum Zitat Chu KC, Smart CR, Taronev RE. Analysis of breast cancer mortality and stage distribution by age for the Health Insurance Plan Clinical Trial. J Natl Cancer Inst. 1998;80:1125–32.CrossRef Chu KC, Smart CR, Taronev RE. Analysis of breast cancer mortality and stage distribution by age for the Health Insurance Plan Clinical Trial. J Natl Cancer Inst. 1998;80:1125–32.CrossRef
4.
Zurück zum Zitat Andersson I, Janzon L. Reduced breast cancer mortality in women under age 50: update results from the Malmo Mammographic Screening Program. J Natl Cancer Inst Monogr. 1997;22:63–7.PubMed Andersson I, Janzon L. Reduced breast cancer mortality in women under age 50: update results from the Malmo Mammographic Screening Program. J Natl Cancer Inst Monogr. 1997;22:63–7.PubMed
5.
Zurück zum Zitat Bjurstam N, Björnald L, Duffy SW, et al. The Gothenburg breast screening trial: first results on mortality, incidence, and mode of detection for women ages 39–49 years at randomization. Cancer. 1997;80:2091–9.PubMedCrossRef Bjurstam N, Björnald L, Duffy SW, et al. The Gothenburg breast screening trial: first results on mortality, incidence, and mode of detection for women ages 39–49 years at randomization. Cancer. 1997;80:2091–9.PubMedCrossRef
6.
Zurück zum Zitat Brown D. Deaths rates from breast cancer fall by a third. BMJ. 2000;321:849.CrossRef Brown D. Deaths rates from breast cancer fall by a third. BMJ. 2000;321:849.CrossRef
7.
Zurück zum Zitat Frisell J, Bidbrink E, Hellstrom L. Rutqvist L.-E. Follow-up after 11 years: update of mortality results in the Stockholm Mammographic Screening Trial. Breast Cancer Res Treat. 1997;45:263–70.PubMedCrossRef Frisell J, Bidbrink E, Hellstrom L. Rutqvist L.-E. Follow-up after 11 years: update of mortality results in the Stockholm Mammographic Screening Trial. Breast Cancer Res Treat. 1997;45:263–70.PubMedCrossRef
8.
Zurück zum Zitat Miller AB, To T, Baines CJ, Wall C. Canadian National Breast Screening Study: I. breast cancer detection and death rates among women aged 40–49 years. Can Med Assoc J. 1992;147:1459–76. Miller AB, To T, Baines CJ, Wall C. Canadian National Breast Screening Study: I. breast cancer detection and death rates among women aged 40–49 years. Can Med Assoc J. 1992;147:1459–76.
9.
Zurück zum Zitat Miller AB, Baines CJ, To T, Wall C. Canadian National Breast Screening Study: II. breast cancer detection and death rates among women aged 50–59 years. Can Med Assoc J. 1992;147:1447–88. Miller AB, Baines CJ, To T, Wall C. Canadian National Breast Screening Study: II. breast cancer detection and death rates among women aged 50–59 years. Can Med Assoc J. 1992;147:1447–88.
10.
Zurück zum Zitat Tabar L, Fagerberg G, Chen HH, et al. Efficacy of breast cancer screening by age: new results from the Swedish two-county trial. Cancer. 1995;75:2507–17.PubMedCrossRef Tabar L, Fagerberg G, Chen HH, et al. Efficacy of breast cancer screening by age: new results from the Swedish two-county trial. Cancer. 1995;75:2507–17.PubMedCrossRef
11.
Zurück zum Zitat Shapiro S, Strax P, Venet L, et al. Ten- to fourteen-year effect of screening on breast cancer mortality. J Nath Cancer Inst. 1982;69:349–55. Shapiro S, Strax P, Venet L, et al. Ten- to fourteen-year effect of screening on breast cancer mortality. J Nath Cancer Inst. 1982;69:349–55.
12.
Zurück zum Zitat Crystal P, Strano SD, Shcharynski S. Koretz MJ Using sonography to screen women with mammographycally dense breast. AJR. 2003;181:177–82.PubMed Crystal P, Strano SD, Shcharynski S. Koretz MJ Using sonography to screen women with mammographycally dense breast. AJR. 2003;181:177–82.PubMed
13.
Zurück zum Zitat Kolb TM, Lichy J, Newhouse JH. Comparation of the performance of screening mammography, physical examination, and breast US and evaluation of factors that influence them: an analysis of 27,825 patients evaluations. Radiology. 2002;225:165–75.PubMedCrossRef Kolb TM, Lichy J, Newhouse JH. Comparation of the performance of screening mammography, physical examination, and breast US and evaluation of factors that influence them: an analysis of 27,825 patients evaluations. Radiology. 2002;225:165–75.PubMedCrossRef
14.
Zurück zum Zitat Liberman L. Breast cancer screening with MRI: what are the data for patients at high risk? New Engl J Med. 2004;351:497–500.PubMedCrossRef Liberman L. Breast cancer screening with MRI: what are the data for patients at high risk? New Engl J Med. 2004;351:497–500.PubMedCrossRef
15.
Zurück zum Zitat Shapiro S. Evidence on screening for breast cancer from a randomized trial. Cancer. 1977;39:2772.PubMedCrossRef Shapiro S. Evidence on screening for breast cancer from a randomized trial. Cancer. 1977;39:2772.PubMedCrossRef
16.
Zurück zum Zitat Humphrey LL, Helfand M, Chan BK, Woolf SH. Breast cancer screening: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2002;137:347–60.PubMed Humphrey LL, Helfand M, Chan BK, Woolf SH. Breast cancer screening: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2002;137:347–60.PubMed
17.
Zurück zum Zitat Smith RA, Duffy SW, Gabe R, et al. The randomized trials of breast cancer screening: what have we learned? Radiol Clini North Am. 2004;42:793–806.CrossRef Smith RA, Duffy SW, Gabe R, et al. The randomized trials of breast cancer screening: what have we learned? Radiol Clini North Am. 2004;42:793–806.CrossRef
18.
Zurück zum Zitat Schopper D, Wolf C. How effective are breast cancer screening programmes by mammography? Review of the current evidence. Eur J Cancer. 2009;45:1916–23.PubMedCrossRef Schopper D, Wolf C. How effective are breast cancer screening programmes by mammography? Review of the current evidence. Eur J Cancer. 2009;45:1916–23.PubMedCrossRef
19.
20.
Zurück zum Zitat Chala LF, Shimizu C, Camargo P. Rastreamento mamográfico na população em geral. In: Frasson A, Millen EC, Novita G, et al., editors.Doenças da mama: guia prático baseado em evidências. São Paulo: Editora Atheneu; 2011. Chala LF, Shimizu C, Camargo P. Rastreamento mamográfico na população em geral. In: Frasson A, Millen EC, Novita G, et al., editors.Doenças da mama: guia prático baseado em evidências. São Paulo: Editora Atheneu; 2011.
21.
Zurück zum Zitat • Smith RA, Cokkinides V, Brawley OW. Cancer screening in the United States, 2009: A review of current American Cancer Society guidelines and issues in cancer screening. CA Cancer J Clin. 2009;59:27–41. Review and recommendations about the breast screening from the American Cancer Society.PubMedCrossRef • Smith RA, Cokkinides V, Brawley OW. Cancer screening in the United States, 2009: A review of current American Cancer Society guidelines and issues in cancer screening. CA Cancer J Clin. 2009;59:27–41. Review and recommendations about the breast screening from the American Cancer Society.PubMedCrossRef
22.
Zurück zum Zitat • Lee CH, Dershaw DD MD, Kopans D, et al. Breast cancer screening with imaging: recommendations from the Society of Breast Imaging and the ACR on the use of mammography, breast MRI, breast ultrasound, and other technologies for the detection of clinically occult breast cancer. Am Coll Radiol. 2010;7:18–27. Review and recommendations about the breast screening from Society of Breast Imaging and the American College of Radiology.CrossRef • Lee CH, Dershaw DD MD, Kopans D, et al. Breast cancer screening with imaging: recommendations from the Society of Breast Imaging and the ACR on the use of mammography, breast MRI, breast ultrasound, and other technologies for the detection of clinically occult breast cancer. Am Coll Radiol. 2010;7:18–27. Review and recommendations about the breast screening from Society of Breast Imaging and the American College of Radiology.CrossRef
23.
Zurück zum Zitat US Preventive Services. Task Force. Screening for Breast Cancer: An Update for the U.S. Preventive Services Task Force. Ann Intern Med. 2009;151:727–37. US Preventive Services. Task Force. Screening for Breast Cancer: An Update for the U.S. Preventive Services Task Force. Ann Intern Med. 2009;151:727–37.
24.
Zurück zum Zitat Bn H, Fw D. Abdsaleh S, et al. Effectiveness of population-based service screening with mammography for women ages 40 to 49 years: evaluation of the Swedish mammography screening in young women cohort. Cancer. 2011;117:714–22.CrossRef Bn H, Fw D. Abdsaleh S, et al. Effectiveness of population-based service screening with mammography for women ages 40 to 49 years: evaluation of the Swedish mammography screening in young women cohort. Cancer. 2011;117:714–22.CrossRef
25.
Zurück zum Zitat US Preventive Services. Task Force. Screening for breast cancer: recommendations and rationale. Ann Intern Med. 2002;137:344–6. US Preventive Services. Task Force. Screening for breast cancer: recommendations and rationale. Ann Intern Med. 2002;137:344–6.
26.
Zurück zum Zitat Smith RA, Saslow D, Sawyer KA, et al. American Cancer Society guidelines for breast cancer screening: update 2003. CA Cancer J Clin. 2003;53:141–69.PubMedCrossRef Smith RA, Saslow D, Sawyer KA, et al. American Cancer Society guidelines for breast cancer screening: update 2003. CA Cancer J Clin. 2003;53:141–69.PubMedCrossRef
27.
Zurück zum Zitat Michaelson JS, Halpern E, Kopans DB. Breast cancer: computer simulation method for estimating optimal intervals for screening. Radiology. 1999;21:551–60. Michaelson JS, Halpern E, Kopans DB. Breast cancer: computer simulation method for estimating optimal intervals for screening. Radiology. 1999;21:551–60.
28.
Zurück zum Zitat Skaane P. Studies comparing screen-film mammography and full-field digital mammography in breast cancer screening: updated review. Acta Radiol. 2009;50:3–14.PubMedCrossRef Skaane P. Studies comparing screen-film mammography and full-field digital mammography in breast cancer screening: updated review. Acta Radiol. 2009;50:3–14.PubMedCrossRef
29.
Zurück zum Zitat Pisano ED, Gatsonis CA, Hendrick RE, et al. Diagnostic accuracy of digital versus film mammography for breast cancer screening. N Engl J Med. 2005;353:1773–83.PubMedCrossRef Pisano ED, Gatsonis CA, Hendrick RE, et al. Diagnostic accuracy of digital versus film mammography for breast cancer screening. N Engl J Med. 2005;353:1773–83.PubMedCrossRef
30.
Zurück zum Zitat Cole E, Pisano ED, Brown M, et al. Diagnostic accuracy of Fischer SenoScan digital mammography versus screen-film mammography in a diagnostic mammography population. Acad Radiol. 2004;11:879–86.PubMedCrossRef Cole E, Pisano ED, Brown M, et al. Diagnostic accuracy of Fischer SenoScan digital mammography versus screen-film mammography in a diagnostic mammography population. Acad Radiol. 2004;11:879–86.PubMedCrossRef
31.
Zurück zum Zitat •• Kalager M. Overdiagnosis of invasive breast cancer due to mammography screening: results from the Norwegian screening program. Ann Intern Med. 2012;156:491–9. Recent study about the overdiagnosis of brest cancer due to mammography screening: An overdiagnosis rate of 15-25% was estimated, which represents 6–10 overdiagnosed women at every 2,500 screened patients.PubMed •• Kalager M. Overdiagnosis of invasive breast cancer due to mammography screening: results from the Norwegian screening program. Ann Intern Med. 2012;156:491–9. Recent study about the overdiagnosis of brest cancer due to mammography screening: An overdiagnosis rate of 15-25% was estimated, which represents 6–10 overdiagnosed women at every 2,500 screened patients.PubMed
32.
Zurück zum Zitat •• Bock K, Borisch B, Cawson J, et al. Effect of population based screening on breast cancer mortality. Lancet. 2011;378:1765–76. Recent publication signed by some leading breast cancer researchers reinforced the importance of MG as public health policy.CrossRef •• Bock K, Borisch B, Cawson J, et al. Effect of population based screening on breast cancer mortality. Lancet. 2011;378:1765–76. Recent publication signed by some leading breast cancer researchers reinforced the importance of MG as public health policy.CrossRef
33.
Zurück zum Zitat Kriege R, Brekelmans CT, Boetes C, et al. Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. New Engl J Med. 2004;351:425–37.CrossRef Kriege R, Brekelmans CT, Boetes C, et al. Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. New Engl J Med. 2004;351:425–37.CrossRef
34.
Zurück zum Zitat Warner E, Plewes DB, Shumak RS, et al. Comparison of breast magnetic resonance imaging, mammography, and ultrasound for surveillance of women at high risk for hereditary breast cancer. J Clinl Oncol. 2001;19:3524–31. Warner E, Plewes DB, Shumak RS, et al. Comparison of breast magnetic resonance imaging, mammography, and ultrasound for surveillance of women at high risk for hereditary breast cancer. J Clinl Oncol. 2001;19:3524–31.
35.
Zurück zum Zitat Warner E, Plewes DB, Hill KA, et al. Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. JAMA. 2004;292:1317–25.PubMedCrossRef Warner E, Plewes DB, Hill KA, et al. Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. JAMA. 2004;292:1317–25.PubMedCrossRef
36.
Zurück zum Zitat Leach MO, Boggis CR, Dixon AK, et al. Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS). Lancet. 2005;365:1769–78.PubMedCrossRef Leach MO, Boggis CR, Dixon AK, et al. Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS). Lancet. 2005;365:1769–78.PubMedCrossRef
37.
Zurück zum Zitat Kuhl CK, Schrading S, Leutner CC, et al. Mammography, breast ultrasound, and magnetic resonance imaging for surveillance of women at high familial risk for breast cancer. J Clin Oncol. 2005;23:8469–76.PubMedCrossRef Kuhl CK, Schrading S, Leutner CC, et al. Mammography, breast ultrasound, and magnetic resonance imaging for surveillance of women at high familial risk for breast cancer. J Clin Oncol. 2005;23:8469–76.PubMedCrossRef
38.
Zurück zum Zitat Kuhl C, Weigel S, Schrading S, et al. Prospective multicenter cohort study to refine management recommendations for women at elevated familial risk of breast cancer: the EVA trial. J Clin Oncol. 2010;20:1450–7.CrossRef Kuhl C, Weigel S, Schrading S, et al. Prospective multicenter cohort study to refine management recommendations for women at elevated familial risk of breast cancer: the EVA trial. J Clin Oncol. 2010;20:1450–7.CrossRef
39.
Zurück zum Zitat Sardanelli F, Podo F, D’Agnolo G, et al. High breast cancer risk Italian trial: Multicenter comparative multimodality surveillance of women at genetic-familial high risk for breast cancer (HIBCRIT study). interim results. Radiology. 2007;242:698–715.PubMedCrossRef Sardanelli F, Podo F, D’Agnolo G, et al. High breast cancer risk Italian trial: Multicenter comparative multimodality surveillance of women at genetic-familial high risk for breast cancer (HIBCRIT study). interim results. Radiology. 2007;242:698–715.PubMedCrossRef
40.
Zurück zum Zitat Lehman CD, Isaacs C, Schnall MD, et al. Cancer yield of mammography, MR, and US in high-risk women: prospective multi-institution breast cancer screening study. Radiology. 2007;244:381–8.PubMedCrossRef Lehman CD, Isaacs C, Schnall MD, et al. Cancer yield of mammography, MR, and US in high-risk women: prospective multi-institution breast cancer screening study. Radiology. 2007;244:381–8.PubMedCrossRef
41.
Zurück zum Zitat Hagen AI, Kvistad KA, Maehle L, et al. Sensitivity of MRI versus conventional screening in the diagnosis of BRCA-associated breast cancer in a national prospective series. Breast. 2007;16:367–74.PubMedCrossRef Hagen AI, Kvistad KA, Maehle L, et al. Sensitivity of MRI versus conventional screening in the diagnosis of BRCA-associated breast cancer in a national prospective series. Breast. 2007;16:367–74.PubMedCrossRef
42.
Zurück zum Zitat Lord SJ, Lei W, Craft P, et al. A systematic review of the effectiveness of magnetic resonance imaging (MRI) as an addition to mammography and ultrasound in screening young women at high risk of breast cancer. Eur J Cancer. 2007;43:1905–17.PubMedCrossRef Lord SJ, Lei W, Craft P, et al. A systematic review of the effectiveness of magnetic resonance imaging (MRI) as an addition to mammography and ultrasound in screening young women at high risk of breast cancer. Eur J Cancer. 2007;43:1905–17.PubMedCrossRef
43.
Zurück zum Zitat Warner E, Messersmith H, Causer P, et al. Systematic review: using magnetic resonance imaging to screen women at high risk for breast cancer. Ann Intern Med. 2008;148:671–9.PubMed Warner E, Messersmith H, Causer P, et al. Systematic review: using magnetic resonance imaging to screen women at high risk for breast cancer. Ann Intern Med. 2008;148:671–9.PubMed
44.
Zurück zum Zitat Tilanus-Linthorst MM, Obdeijn IM, Hop WCJ, et al. BRCA1 mutation and young age predict fast breast cancer growth in the Dutch, United Kingdom, and Canadian magnetic resonance imaging screening trials. Clin Cancer Res. 2007;13:7357–62.PubMedCrossRef Tilanus-Linthorst MM, Obdeijn IM, Hop WCJ, et al. BRCA1 mutation and young age predict fast breast cancer growth in the Dutch, United Kingdom, and Canadian magnetic resonance imaging screening trials. Clin Cancer Res. 2007;13:7357–62.PubMedCrossRef
45.
Zurück zum Zitat • Sardanelli F, Boetes C, Borisch B, et al. Magnetic resonance imaging of the breast: recommendations from the EUSOMA working group. Eur J Cancer. 2010:1286–316. Review and recommendations about the MRI screening from EUROMA working group. • Sardanelli F, Boetes C, Borisch B, et al. Magnetic resonance imaging of the breast: recommendations from the EUSOMA working group. Eur J Cancer. 2010:1286–316. Review and recommendations about the MRI screening from EUROMA working group.
46.
Zurück zum Zitat National Collaborating Centre for Primary Care. Familial breast cancer: the classification and care of women at risk of familial breast cancer in primary, secondary and tertiary care (partial update of CG14). 2006;1–75. National Collaborating Centre for Primary Care. Familial breast cancer: the classification and care of women at risk of familial breast cancer in primary, secondary and tertiary care (partial update of CG14). 2006;1–75.
47.
Zurück zum Zitat Plevritis SK, Kurian AW, Sigal BM, et al. Cost-effectiveness of screening BRCA1/2 mutation carriers with breast magnetic resonance imaging. JAMA. 2006;295:2374–84.PubMedCrossRef Plevritis SK, Kurian AW, Sigal BM, et al. Cost-effectiveness of screening BRCA1/2 mutation carriers with breast magnetic resonance imaging. JAMA. 2006;295:2374–84.PubMedCrossRef
48.
Zurück zum Zitat •• Saslow D, Boetes C, Burke W, et al. American Cancer Society guidelines for breast cancer screening with MRI as an adjunct to mammography. CA Cancer J Clin. 2007;57:75–89. Recommendations about the MRI screening from the America Cancer Society.PubMedCrossRef •• Saslow D, Boetes C, Burke W, et al. American Cancer Society guidelines for breast cancer screening with MRI as an adjunct to mammography. CA Cancer J Clin. 2007;57:75–89. Recommendations about the MRI screening from the America Cancer Society.PubMedCrossRef
49.
Zurück zum Zitat Dogan BE, Gonzalez-Angulo AM, Gilcrease M, et al. Multimodality imaging of triple receptor-negative tumors with mammography, ultrasound, and MRI. AJR. 2010;194:1160–6.PubMedCrossRef Dogan BE, Gonzalez-Angulo AM, Gilcrease M, et al. Multimodality imaging of triple receptor-negative tumors with mammography, ultrasound, and MRI. AJR. 2010;194:1160–6.PubMedCrossRef
50.
Zurück zum Zitat Wang Y, Ikeda DM, Narasimhan B, et al. Estrogen receptor-negative invasive breast cancer: imaging features of tumors with and without human epidermal growth factor receptor type 2 overexpression. Radiology. 2008;246:367–75.PubMedCrossRef Wang Y, Ikeda DM, Narasimhan B, et al. Estrogen receptor-negative invasive breast cancer: imaging features of tumors with and without human epidermal growth factor receptor type 2 overexpression. Radiology. 2008;246:367–75.PubMedCrossRef
51.
Zurück zum Zitat Yang WT, Dryden M, Broglio K, et al. Mammographic features of triple receptor-negative primary breast cancers in young premenopausal women. Breast Cancer ResTreat. 2008;111:405–10.CrossRef Yang WT, Dryden M, Broglio K, et al. Mammographic features of triple receptor-negative primary breast cancers in young premenopausal women. Breast Cancer ResTreat. 2008;111:405–10.CrossRef
52.
Zurück zum Zitat Schrading S, Kuhl CK. Mammographic, US and MR imaging phenotypes of familial breast cancer. Radiology. 2008;246:58–70.PubMed Schrading S, Kuhl CK. Mammographic, US and MR imaging phenotypes of familial breast cancer. Radiology. 2008;246:58–70.PubMed
53.
Zurück zum Zitat •• Morrow M, Waters J, Morris E. MRI for breast cancer screening, diagnosis, and treatment. Lancet. 2011;378:1804–11. This study did a critical analysis of the main indications of breast MRI, with concerns about breast screening.PubMedCrossRef •• Morrow M, Waters J, Morris E. MRI for breast cancer screening, diagnosis, and treatment. Lancet. 2011;378:1804–11. This study did a critical analysis of the main indications of breast MRI, with concerns about breast screening.PubMedCrossRef
54.
Zurück zum Zitat Taneja C, Edelsberg J, Weycker D, et al. Cost effectiveness of breast cancer screening with contrast-enhanced MRI in high-risk women. J Am Coll Radiol. 2009;6:171–9.PubMedCrossRef Taneja C, Edelsberg J, Weycker D, et al. Cost effectiveness of breast cancer screening with contrast-enhanced MRI in high-risk women. J Am Coll Radiol. 2009;6:171–9.PubMedCrossRef
Metadaten
Titel
Role of Mammography versus Magnetic Resonance Imaging for Breast Cancer Screening
verfasst von
Linei Urban
Cícero Urban
Publikationsdatum
01.09.2012
Verlag
Current Science Inc.
Erschienen in
Current Breast Cancer Reports / Ausgabe 3/2012
Print ISSN: 1943-4588
Elektronische ISSN: 1943-4596
DOI
https://doi.org/10.1007/s12609-012-0085-5

Weitere Artikel der Ausgabe 3/2012

Current Breast Cancer Reports 3/2012 Zur Ausgabe

Invited Commentary

Is HER2 Through?

Risk, Prevention, and Screening (MC Liu, Section Editor)

Options for Surgical Prophylaxis and Reconstruction

Risk, Prevention, and Screening (MC Liu, Section Editor)

Tamoxifen versus Raloxifene versus Exemestane for Chemoprevention

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.